251 related articles for article (PubMed ID: 27357360)
1. Unfavorable neuroblastoma prognostic factor NLRR2 inhibits cell differentiation by transcriptional induction through JNK pathway.
Sheikh A; Takatori A; Hossain MS; Hasan MK; Tagawa M; Nagase H; Nakagawara A
Cancer Sci; 2016 Sep; 107(9):1223-32. PubMed ID: 27357360
[TBL] [Abstract][Full Text] [Related]
2. Expression of NLRR3 orphan receptor gene is negatively regulated by MYCN and Miz-1, and its downregulation is associated with unfavorable outcome in neuroblastoma.
Akter J; Takatori A; Hossain MS; Ozaki T; Nakazawa A; Ohira M; Suenaga Y; Nakagawara A
Clin Cancer Res; 2011 Nov; 17(21):6681-92. PubMed ID: 21908575
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel human neuronal leucine-rich repeat (hNLRR) family genes and inverse association of expression of Nbla10449/hNLRR-1 and Nbla10677/hNLRR-3 with the prognosis of primary neuroblastomas.
Hamano S; Ohira M; Isogai E; Nakada K; Nakagawara A
Int J Oncol; 2004 Jun; 24(6):1457-66. PubMed ID: 15138588
[TBL] [Abstract][Full Text] [Related]
4. Induction of cyclin-dependent kinase 5 and its activator p35 through the extracellular-signal-regulated kinase and protein kinase A pathways during retinoic-acid mediated neuronal differentiation in human neuroblastoma SK-N-BE(2)C cells.
Lee JH; Kim KT
J Neurochem; 2004 Nov; 91(3):634-47. PubMed ID: 15485494
[TBL] [Abstract][Full Text] [Related]
5. Long Noncoding RNA NHEG1 Drives β-Catenin Transactivation and Neuroblastoma Progression through Interacting with DDX5.
Zhao X; Li D; Yang F; Lian H; Wang J; Wang X; Fang E; Song H; Hu A; Guo Y; Liu Y; Li H; Chen Y; Huang K; Zheng L; Tong Q
Mol Ther; 2020 Mar; 28(3):946-962. PubMed ID: 31982037
[TBL] [Abstract][Full Text] [Related]
6. Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastoma.
Ikram F; Ackermann S; Kahlert Y; Volland R; Roels F; Engesser A; Hertwig F; Kocak H; Hero B; Dreidax D; Henrich KO; Berthold F; Nürnberg P; Westermann F; Fischer M
Mol Oncol; 2016 Feb; 10(2):344-59. PubMed ID: 26598443
[TBL] [Abstract][Full Text] [Related]
7. HDAC inhibitors suppress c-Jun/Fra-1-mediated proliferation through transcriptionally downregulating MKK7 and Raf1 in neuroblastoma cells.
He W; Wu Y; Tang X; Xia Y; He G; Min Z; Li C; Xiong S; Shi Z; Lu Y; Yuan Z
Oncotarget; 2016 Feb; 7(6):6727-47. PubMed ID: 26734995
[TBL] [Abstract][Full Text] [Related]
8. miRNA-558 promotes tumorigenesis and aggressiveness of neuroblastoma cells through activating the transcription of heparanase.
Qu H; Zheng L; Pu J; Mei H; Xiang X; Zhao X; Li D; Li S; Mao L; Huang K; Tong Q
Hum Mol Genet; 2015 May; 24(9):2539-51. PubMed ID: 25616966
[TBL] [Abstract][Full Text] [Related]
9. EZH2 regulates neuroblastoma cell differentiation via NTRK1 promoter epigenetic modifications.
Li Z; Takenobu H; Setyawati AN; Akita N; Haruta M; Satoh S; Shinno Y; Chikaraishi K; Mukae K; Akter J; Sugino RP; Nakazawa A; Nakagawara A; Aburatani H; Ohira M; Kamijo T
Oncogene; 2018 May; 37(20):2714-2727. PubMed ID: 29507419
[TBL] [Abstract][Full Text] [Related]
10. The proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathway.
Luo P; Lin M; Li L; Yang B; He Q
PLoS One; 2011; 6(11):e27298. PubMed ID: 22087283
[TBL] [Abstract][Full Text] [Related]
11. NLRR1 enhances EGF-mediated MYCN induction in neuroblastoma and accelerates tumor growth in vivo.
Hossain S; Takatori A; Nakamura Y; Suenaga Y; Kamijo T; Nakagawara A
Cancer Res; 2012 Sep; 72(17):4587-96. PubMed ID: 22815527
[TBL] [Abstract][Full Text] [Related]
12.
Maeshima R; Moulding D; Stoker AW; Hart SL
Nucleic Acid Ther; 2020 Aug; 30(4):237-248. PubMed ID: 32240058
[TBL] [Abstract][Full Text] [Related]
13. The PLAGL2/MYCN/miR-506-3p interplay regulates neuroblastoma cell fate and associates with neuroblastoma progression.
Zhao Z; Shelton SD; Oviedo A; Baker AL; Bryant CP; Omidvarnia S; Du L
J Exp Clin Cancer Res; 2020 Feb; 39(1):41. PubMed ID: 32087738
[TBL] [Abstract][Full Text] [Related]
14. Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.
Yang XH; Tang F; Shin J; Cunningham JM
BMC Syst Biol; 2017 Oct; 11(Suppl 5):92. PubMed ID: 28984200
[TBL] [Abstract][Full Text] [Related]
15. HMGI(Y) and HMGI-C genes are expressed in neuroblastoma cell lines and tumors and affect retinoic acid responsiveness.
Giannini G; Di Marcotullio L; Ristori E; Zani M; Crescenzi M; Scarpa S; Piaggio G; Vacca A; Peverali FA; Diana F; Screpanti I; Frati L; Gulino A
Cancer Res; 1999 May; 59(10):2484-92. PubMed ID: 10344762
[TBL] [Abstract][Full Text] [Related]
16. Notch1 expression predicts an unfavorable prognosis and serves as a therapeutic target of patients with neuroblastoma.
Chang HH; Lee H; Hu MK; Tsao PN; Juan HF; Huang MC; Shih YY; Wang BJ; Jeng YM; Chang CL; Huang SF; Tsay YG; Hsieh FJ; Lin KH; Hsu WM; Liao YF
Clin Cancer Res; 2010 Sep; 16(17):4411-20. PubMed ID: 20736329
[TBL] [Abstract][Full Text] [Related]
17. Dihydropyrimidinase-like protein 3 expression is negatively regulated by MYCN and associated with clinical outcome in neuroblastoma.
Tan F; Wahdan-Alaswad R; Yan S; Thiele CJ; Li Z
Cancer Sci; 2013 Dec; 104(12):1586-92. PubMed ID: 24011394
[TBL] [Abstract][Full Text] [Related]
18. The deubiquitinating enzyme UCHL1 is a favorable prognostic marker in neuroblastoma as it promotes neuronal differentiation.
Gu Y; Lv F; Xue M; Chen K; Cheng C; Ding X; Jin M; Xu G; Zhang Y; Wu Z; Zheng L; Wu Y
J Exp Clin Cancer Res; 2018 Oct; 37(1):258. PubMed ID: 30359286
[TBL] [Abstract][Full Text] [Related]
19. Retinoic acid and cAMP differentially regulate human chromogranin A promoter activity during differentiation of neuroblastoma cells.
Gaetano C; Manni I; Bossi G; Piaggio G; Soddu S; Farina A; Helman LJ; Sacchi A
Eur J Cancer; 1995; 31A(4):447-52. PubMed ID: 7576943
[TBL] [Abstract][Full Text] [Related]
20. Dyngo-4a Induces Neuroblastoma Cell Differentiation Through The AKT and ERK1/2 Pathway.
Huang J; Zhou Y; Zeng S; Xu J; Liu L; Grothusen J; Liu R
CNS Neurol Disord Drug Targets; 2023; 22(10):1526-1534. PubMed ID: 36476431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
